The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -20,196 | -20,919 | -20,283 | -58,759 |
| Reduction in the carrying amount of rou assets, operating | 393 | 385 | 377 | 729 |
| Reduction in the carrying amount of rou assets, finance | 80 | 80 | 80 | 160 |
| Stock based compensation expense | 2,755 | 2,713 | 2,651 | 6,768 |
| Depreciation and amortization expense | 73 | 73 | 73 | 122 |
| Non-cash gain on long-term investment | - | 0 | 0 | 3,390 |
| Net realized gain on investments in u.s. treasury securities | - | 17 | - | - |
| Amortization of premium (accretion of discount) on investments in u.s. treasury securities | 42 | -5 | -60 | -46 |
| Prepaid expenses and other current assets | 1,119 | 1,578 | -2,140 | 2,566 |
| Accounts payable | -1,596 | 200 | -15,268 | 13,507 |
| Accrued expenses and other current liabilities | -1,092 | -619 | 996 | -4,822 |
| Lease liabilities, operating | -402 | -394 | -381 | -721 |
| Lease liabilities, finance | 2 | -8 | 8 | -9 |
| Net cash used in operating activities | -21,144 | -20,079 | -29,547 | -48,935 |
| Purchase of property and equipment | 35 | 0 | 289 | 108 |
| Purchases of investments | - | 140,016 | 0 | 55,366 |
| Proceeds from sales or maturities of investments | 27,495 | 38,327 | 35,300 | 31,900 |
| Net cash provided by investing activities | 27,460 | -101,689 | 35,011 | -23,574 |
| Proceeds from issuance of common stock, pre-funded warrants and warrants to purchase common stock upon may 2025 private placement offering | - | - | 0 | 79,999 |
| Proceeds from issuance of common stock, pre-funded warrants and warrants to purchase common stock upon may 2025 private placement | - | 79,999 | - | - |
| Proceeds from exercise of common warrants | 2,446 | - | - | - |
| Payment of financing and stock issuance costs | - | 0 | 0 | 6,917 |
| Proceeds from exercise of stock options | 9 | 25 | 34 | - |
| Payments on finance leases | 121 | 169 | 83 | 281 |
| Proceeds from issuance of common stock and pre-funded warrants to purchase common stock upon october 2025 financing transactions | - | 153,750 | - | - |
| Proceeds from common stock issuances under 2023 espp | 143 | -1 | 101 | 170 |
| Third-party commissions and offering costs incurred upon october 2025 financing transactions | 25 | 9,833 | - | - |
| Net cash provided by financing activities | 2,452 | 143,772 | 52 | 72,971 |
| Net change in cash, cash equivalents and restricted cash | 8,768 | 22,004 | 5,516 | 462 |
| Cash, cash equivalents and restricted cash at beginning of period | 66,248 | 44,244 | 38,266 | - |
| Cash, cash equivalents and restricted cash at end of period | 75,016 | 66,248 | 44,244 | - |
Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc. (LXEO)